DICE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 Aug 2023 @ 16:00):

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas...

Stats
Today's Volume	4.33M
Average Volume	1.75M
Market Cap	2.27B
EPS	$0 ( 2024-05-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.91
ATR14	$0.513 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-09	Ra Capital Management, L.p.	Sell	786 407	Common Stock
2023-08-09	Ra Capital Management, L.p.	Sell	21 250	Stock Option (Right to Buy)
2023-08-09	Tetlow Sharon	Sell	49 841	Common Stock
2023-08-09	Tetlow Sharon	Sell	13 800	Stock Option (right to buy)
2023-08-09	Tetlow Sharon	Sell	21 250	Stock Option (right to buy)

INSIDER POWER
-59.34
Last 99 transactions
Buy: 13 025 781 \| Sell: 10 716 392

Volume Correlation

Long: 0.25 (neutral)

Short: 0.00 (neutral)

Signal:(77.583) Neutral

DICE Therapeutics, Inc. Correlation

10 Most Positive Correlations
KDNY	0.925
CPAA	0.816

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DICE Therapeutics, Inc. Correlation - Currency/Commodity

0.78
( moderate )

0.65
( moderate )

-0.77
( moderate negative )

0.91
( very strong )

-0.25
( neutral )

DICE Therapeutics, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.07

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.07

FY	2021
Revenue:	$1.13M
Gross Profit:	$1.13M (100.00 %)
EPS:	$-2.11

FY	2020
Revenue:	$863 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.020

Financial Reports:

No articles found.

DICE Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

DICE Therapeutics, Inc.

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.